Beleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the last few years, and now the biotech is cutting a clinical antibody-drug conjugate program from its mid-stage lineup.
Kyntra announced in a third-quarter earnings report that it would be dropping a phase 2 study of the CD46-targeting ADC FG-3246 in metastatic castration-resistant prostate cancer due to an unmet efficacy threshold, shuttering the program altogether. FG-3180, an accompanying PET imaging candidate, has also been terminated.
Once a promising clinical candidate poised to reverse some of the company’s ill fortunes, Kyntra’s acquired FG-3246 showed “encouraging” phase 1 results, according to analysts at the time, positioned to make a splash in the prostate cancer space if further trials panned out.
The win was welcome news in light of the company’s previous stumbles, including an FDA rejection in kidney disease and later trial failure in anemia for its lead candidate roxadustat, debilitating layoffs and federal allegations of fraud leading to a massive SEC settlement.
Now, with a phase 3 trial of roxadustat in anemia planned for the first quarter of 2027, Kyntra is hanging on by a thread, pinning its hopes on “either a strategic partnership or an external capital raise” to get the study going.
Roxadustat was once the subject of a high-profile partnership with pharma giant AstraZeneca beginning in 2013, terminated in 2024. AstraZeneca last year purchased Kyntra’s China business for $160 million.
The program termination is expected to save Kyntra more than $20 million in operating expenses over the next two years, according to the earnings report. At the end of the third quarter, the company reported just over $44 million in holdings, including cash, cash equivalents, investments and accounts receivable, which it said would be enough to last through 2028.
Kyntra brought in total third-quarter revenue of $1.8 million, up from $1.1 million a year prior. Roxadustat, known as Evrenzo, is its only approved product in Europe, Japan, China and other countries, but not in the U.S.